Inventor · disambiguated record
Berkley A. Lynch
Also filed as: LYNCH BERKLEY · LYNCH BERKLEY A
4 granted patents·7 pending applications·165 citations·filing 1995–2024
80Inventor score
Top patents by PatentIndex Score
11 records- 0185US5710129AInhibitors of SH2-mediated processesARIAD PHARMA INC·Filed 1995·Granted Jan 20, 1998·61 cites·8 claims
- 0283US6207397B1In vitro fluorescence polarization assayARIAD PHARMA INC·Filed 1997·Granted Mar 27, 2001·80 cites·11 claims
- 0373US7090985B2Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseasesUCB SA·Filed 2002·Granted Aug 15, 2006·15 cites·24 claims
- 0472US7465549B2Methods for identifying agents that bind a levetiracetam binding site (LBS) or compete with LEV binding to a LBS of a synaptic vesicle protein 2 (SV2)UCB SA·Filed 2003·Granted Dec 16, 2008·9 cites·38 claims
- 0571US2025326839A1Treatment of diseases related to colony-stimulating factor 1 receptor dysfunction using trem2 agonistsVIGIL NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 0660US2022089726A1Treatment of diseases related to colony-stimulating factor 1 receptor dysfunction using trem2 agonistsVIGIL NEUROSCIENCE INC·Filed 2021·Application pending·0 cites
- 0754US2010160372A1Treatment of proteinopathies using a farnesyl transferase inhibitorLINK MEDICINE CORP·Filed 2009·Application pending·0 cites
- 0854US2024270843A1Trem2 agonist biomarkers and methods of use thereofVIGIL NEUROSCIENCE INC·Filed 2022·Application pending·0 cites
- 0950US2011294794A1Treatment of proteinopathies using a farnesyl transferase inhibitorLANSBURY JR PETER T·Filed 2009·Application pending·0 cites
- 1029US2010331363A1Treatment of mitochondrial disorders using a farnesyl transferase inhibitorLINK MEDICINE CORP·Filed 2010·Application pending·0 cites
- 1129US2011060005A1Treatment of mitochondrial disorders using a farnesyl transferase inhibitorLINK MEDICINE CORP·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →